Magnesium Bisglycinate

Within the SIRIAM Platform, Magnesium Bisglycinate is classified as a Regional Signature Component.

Unlike the Structural & Dermal Support Core, Release Core and Integration Core ingredients, Magnesium Bisglycinate is incorporated selectively into regional formulations according to their intended neurodermal objectives.

Within the SIRIAM formulation philosophy, Magnesium Bisglycinate represents a highly bioavailable organic magnesium complex selected not for systemic supplementation, but for its contribution to the biological architecture of selected topical formulations. It complements the platform by introducing a physiologically important mineral cofactor with excellent dermal compatibility.

Its inclusion reflects the SIRIAM principle of combining essential micronutrients with region-specific neurodermal formulation design.

Magnesium Bisglycinate consists of elemental magnesium chelated to two molecules of the amino acid glycine, producing a stable organic complex with excellent gastrointestinal absorption when administered orally.

Magnesium is the second most abundant intracellular cation and functions as an essential cofactor for more than 300 enzymatic reactions, including those involved in:

ATP synthesis;

mitochondrial energy metabolism;

protein synthesis;

nucleic acid metabolism;

calcium regulation;

neuronal excitability;

muscle contraction and relaxation;

antioxidant defence.

The glycine ligand contributes chemical stability and may improve biological compatibility compared with certain inorganic magnesium salts.

Extensive clinical evidence supports oral Magnesium Bisglycinate for the correction of magnesium deficiency and suggests potential benefits in:

muscle cramps;

neuromuscular excitability;

sleep quality;

stress-related symptoms;

migraine prevention;

selected chronic pain conditions.

Evidence supporting topical magnesium therapy is considerably less robust.

Although transdermal magnesium preparations have become increasingly popular, systematic reviews conclude that convincing evidence for clinically meaningful magnesium absorption through intact human skin remains limited. Nevertheless, experimental studies suggest that topical magnesium formulations may exert:

local skin-conditioning effects;

improvements in epidermal hydration;

modulation of inflammatory signalling;

favourable effects on skin barrier physiology.

Whether these effects are mediated by significant magnesium absorption or by local physicochemical interactions remains uncertain.

No published studies currently investigate topical Magnesium Bisglycinate within a region-specific neurodermal formulation architecture comparable to the SIRIAM Platform.

Accordingly, its inclusion reflects biological plausibility together with the architectural philosophy of the platform rather than established evidence for this specific pharmaceutical application.

Within the SIRIAM Platform, Magnesium Bisglycinate functions as a Regional Signature Component.

Its architectural role is to contribute an essential mineral cofactor to selected regional formulations while maintaining compatibility with the broader pharmaceutical platform architecture.

Future optimisation may refine concentration according to formulation objectives and pharmaceutical validation.